- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EVOMMUNE Aktie jetzt für 0€ handeln | |||||
| Fr | Evommune übertrifft Verlustprognosen - Aktie legt zu | 3 | Investing.com Deutsch | ||
| Fr | Evommune, Inc. GAAP EPS of -$0.64 | 1 | Seeking Alpha | ||
| 07.05. | Evommune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.04. | Evommune, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 17.04. | Evommune stock price target reaffirmed at $50 by H.C. Wainwright | 5 | Investing.com | ||
| 13.04. | Evommune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.04. | Oppenheimer initiates Evommune stock rating at Outperform, $50 target | 4 | Investing.com | ||
| 07.04. | Evommune: Oppenheimer startet Coverage mit "Outperform" und sieht über 100 % Kurspotenzial | 4 | Investing.com Deutsch | ||
| 18.03. | H.C. Wainwright cuts Evommune stock price target on dilution | 8 | Investing.com | ||
| 18.03. | This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday | 1 | Benzinga.com | ||
| 17.03. | Clear Street initiates Evommune stock with buy rating on drug potential | 4 | Investing.com | ||
| 12.03. | Leerink reiterates Evommune stock rating after conference chat | 1 | Investing.com | ||
| 11.03. | Evommune: RBC Capital startet Coverage mit "Outperform" und sieht 100 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 11.03. | RBC Capital initiates Evommune stock with outperform rating | 1 | Investing.com | ||
| 06.03. | Evommune, Inc Loss At -$28.27 Mln In Q4 | - | RTTNews | ||
| 06.03. | Evommune, Inc. GAAP EPS of -$11.22, revenue of $13M | 1 | Seeking Alpha | ||
| 05.03. | Evommune, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 05.03. | Evommune, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | Evommune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.02. | Evommune beschafft 125 Millionen US-Dollar über Privatplatzierung für Forschung und Entwicklung | 3 | Investing.com Deutsch |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ATAIBECKLEY | 3,680 | +1,66 % | Trump zündet den Turbo: Warum AtaiBeckley und Emyria jetzt im Fokus der Anleger stehen | ||
| ROCKET PHARMACEUTICALS | 3,100 | +0,98 % | ROCKET PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| CORCEPT THERAPEUTICS | 48,080 | -1,44 % | Corcept Therapeutics climbs on UBS upgrade | ||
| KURA ONCOLOGY | 7,760 | -4,20 % | Kura Oncology, Inc.: Kura Oncology Reports First Quarter 2026 Financial Results | - $5.8 million in KOMZIFTI (ziftomenib) net product revenue in first full quarter of commercialization - - Robust new patient starts and early launch dynamics, including repeat use, switching and... ► Artikel lesen | |
| CELCUITY | 107,00 | 0,00 % | Aktien New York Ausblick: Kleines Minus - Iran-Krieg bleibt im Fokus | NEW YORK (dpa-AFX) - Die US-Börsen dürften am Montag vor allem durch Meldungen rund um den Iran-Krieg bewegt werden. Das zeigte bereits das vorbörslich hektische Auf und Ab mit einer zuletzt nur noch... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,220 | 0,00 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TARSUS PHARMACEUTICALS | 64,66 | 0,00 % | Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales | ||
| BICARA THERAPEUTICS | 20,990 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,690 | 0,00 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| PRAXIS PRECISION MEDICINES | 346,46 | -0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,330 | 0,00 % | Allogene Therapeutics Q1 2026 Earnings Call Transcript | ||
| TANGO THERAPEUTICS | 25,510 | 0,00 % | Jefferies downgrades Tango Therapeutics stock rating on valuation | ||
| C4 THERAPEUTICS | 3,660 | -0,54 % | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 117,82 | -0,11 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| BIOVENTUS | 10,400 | 0,00 % | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15... ► Artikel lesen |
Das Unternehmen EVOMMUNE INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,030 (-0,13 %) liegt der Kurs bei 23,210 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOMMUNE INC finden Sie auf Wallstreet Online.